T
Telix Pharmaceuticals Ltd. D
D
TLX
9.53000
USD
-0.49
(-4.89%)
قبل الجلسة·9.60000USD+0.07000(+0.73%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
19,364
الربح لكل سهم
0
العائد الربحي
-
P/E
97
حجم السوق
3,238,144,322
العنوان: Telix Pharmaceuticals Ltd.
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.